Effects of Multiple Oral Doses of an A1 Adenosine Antagonist, BG9928, in Patients With Heart Failure

Effects of Multiple Oral Doses of an A1 Adenosine Antagonist, BG9928, in Patients With Heart Failure: Results of a Placebo-Controlled, Dose-Escalation Study Barry Greenberg, Ignatius Thomas, Dorothy Banish, Steven Goldman, Edward Havranek, Barry M. Massie, Ying Zhu, Barry Ticho, William T. Abraham This multicenter, randomized, double-blind, placebo-controlled study assessed the pharmacokinetics and clinical effects of multiple oral doses of BG9928, a selective inhibitor of the A1 adenosine receptor, in patients with heart failure and systolic dysfunction who were receiving standard therapy. BG9928 over the dose range of 3 to 225 mg/day for 10 days was well tolerated and produced significant increases in sodium excretion without reducing renal function.